Xgeva denosumab regulatory update

FDA's Oncologic Drugs Advisory Committee will meet on Feb. 8 to discuss an sBLA from Amgen for Xgeva denosumab to prevent bone metastases in men with castration-resistant prostate cancer (CRPC). The P...